Eli Lilly was boosted Tuesday afternoon after the Food and Drug Administration approved its Alzheimer's drug, donanemab. It targets and clears amyloid plaque, though such drugs carry safety risks. The market for such treatments is large, with almost 700万 Americans suffering from Alzheimer's.
102188459 : Tq
Venture Eagle : 拜登让股价大幅下跌
John H Bradberry Venture Eagle : 不是真的,因为他保持现状的心态,投资公司很少被他的言行所动摇。你可能不喜欢这个人,但他在市场上做得很好